CytomX Therapeutics Inc. (CTMX) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for CytomX Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$2.36
+2.16% today
Market cap
$503M
Overall quality
40/100
Kronos AI 30-day
+40.5%
8 of 8 simulated paths end higher
CytomX Therapeutics Inc. (CTMX) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $503M. It trades at $2.36, up 2.16% today. Its overall quality score is 40 out of 100, ranked against the whole US market. 5 analysts' average target of $13.00 implies +450.8% from today's price. Kronos AI's 30-day forecast is +40.5% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $13.00 |
| Low – high | $11.00 – $16.00 |
| Analysts | 5 |
| Upside to average | +450.8% |
Kronos AI 30-day forecast
| Expected close | $3.25 (+40.5%) |
| Likely range | +29.9% … +54.2% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 11 |
| Solvency | 59 |
| Growth | 50 |
| Overall | 40 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.